Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA
Objectives To explore whether monoclonal antibodies (MAb) administered to high-risk patients with COVID-19 during the first week of illness prevent postacute sequelae of SARS-CoV-2 infection.Design Retrospective cohort study.Setting USA.Participants A sample of 3809 individuals who received MAbs and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/8/e069247.full |
| _version_ | 1797749928653488128 |
|---|---|
| author | Sarah E Daugherty Yinglong Guo Daniel Griffin Chace McNeil James Okusa Diana Berrent |
| author_facet | Sarah E Daugherty Yinglong Guo Daniel Griffin Chace McNeil James Okusa Diana Berrent |
| author_sort | Sarah E Daugherty |
| collection | DOAJ |
| description | Objectives To explore whether monoclonal antibodies (MAb) administered to high-risk patients with COVID-19 during the first week of illness prevent postacute sequelae of SARS-CoV-2 infection.Design Retrospective cohort study.Setting USA.Participants A sample of 3809 individuals who received MAbs and a matched one-to-one comparison group from a set of 327 079 eligible patients who did not receive MAb treatment were selected from a deidentified administrative data set from commercial and Medicare Advantage health plan enrollees in the USA, including claims and outpatient laboratory data.Results Individuals who received MAb were 28% less likely to be hospitalised (HR=0.72, 95% CI 0.58 to 0.89) and 41% less likely to be admitted to the intensive care unit (HR=0.59, 95% CI 0.38 to 0.89) 30 days from SARS-CoV-2 diagnosis compared with individuals who did not receive MAb. A higher proportion of individuals given MAb therapy received care for clinical sequelae in the postacute phase (p=0.018).Conclusions While MAb therapy was associated with benefits in the acute period, the benefit of therapy did not extend into the postacute period and did not reduce risk for clinical sequelae. |
| first_indexed | 2024-03-12T16:26:36Z |
| format | Article |
| id | doaj.art-92d08674a7a8467fbdeb2507fe2e5ef7 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2024-03-12T16:26:36Z |
| publishDate | 2023-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-92d08674a7a8467fbdeb2507fe2e5ef72023-08-08T17:00:06ZengBMJ Publishing GroupBMJ Open2044-60552023-08-0113810.1136/bmjopen-2022-069247Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USASarah E Daugherty0Yinglong Guo1Daniel Griffin2Chace McNeil3James Okusa4Diana Berrent5OptumLabs at UnitedHealth Group, Minneapolis, MN, USAdirector of data scienceDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USAOptum Health, Eden Prairie, Minnesota, USAOptum Health, Eden Prairie, Minnesota, USASurvivor Corps, New York City, New York, USAObjectives To explore whether monoclonal antibodies (MAb) administered to high-risk patients with COVID-19 during the first week of illness prevent postacute sequelae of SARS-CoV-2 infection.Design Retrospective cohort study.Setting USA.Participants A sample of 3809 individuals who received MAbs and a matched one-to-one comparison group from a set of 327 079 eligible patients who did not receive MAb treatment were selected from a deidentified administrative data set from commercial and Medicare Advantage health plan enrollees in the USA, including claims and outpatient laboratory data.Results Individuals who received MAb were 28% less likely to be hospitalised (HR=0.72, 95% CI 0.58 to 0.89) and 41% less likely to be admitted to the intensive care unit (HR=0.59, 95% CI 0.38 to 0.89) 30 days from SARS-CoV-2 diagnosis compared with individuals who did not receive MAb. A higher proportion of individuals given MAb therapy received care for clinical sequelae in the postacute phase (p=0.018).Conclusions While MAb therapy was associated with benefits in the acute period, the benefit of therapy did not extend into the postacute period and did not reduce risk for clinical sequelae.https://bmjopen.bmj.com/content/13/8/e069247.full |
| spellingShingle | Sarah E Daugherty Yinglong Guo Daniel Griffin Chace McNeil James Okusa Diana Berrent Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA BMJ Open |
| title | Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA |
| title_full | Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA |
| title_fullStr | Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA |
| title_full_unstemmed | Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA |
| title_short | Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA |
| title_sort | does monoclonal antibody treatment for covid 19 impact short and long term outcomes in a large generalisable population a retrospective cohort study in the usa |
| url | https://bmjopen.bmj.com/content/13/8/e069247.full |
| work_keys_str_mv | AT sarahedaugherty doesmonoclonalantibodytreatmentforcovid19impactshortandlongtermoutcomesinalargegeneralisablepopulationaretrospectivecohortstudyintheusa AT yinglongguo doesmonoclonalantibodytreatmentforcovid19impactshortandlongtermoutcomesinalargegeneralisablepopulationaretrospectivecohortstudyintheusa AT danielgriffin doesmonoclonalantibodytreatmentforcovid19impactshortandlongtermoutcomesinalargegeneralisablepopulationaretrospectivecohortstudyintheusa AT chacemcneil doesmonoclonalantibodytreatmentforcovid19impactshortandlongtermoutcomesinalargegeneralisablepopulationaretrospectivecohortstudyintheusa AT jamesokusa doesmonoclonalantibodytreatmentforcovid19impactshortandlongtermoutcomesinalargegeneralisablepopulationaretrospectivecohortstudyintheusa AT dianaberrent doesmonoclonalantibodytreatmentforcovid19impactshortandlongtermoutcomesinalargegeneralisablepopulationaretrospectivecohortstudyintheusa |